Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LVGN7409 + LVGN3616
- Development stage
- Unknown
- Lead developer
- Lijin Biomedical Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Combination of **dalnicastobart (LVGN7409)**, a CD40 agonist monoclonal antibody, and **pradusinstobart (LVGN3616)**, a humanized monoclonal antibody that blocks PD-1 (programmed cell death protein 1). LVGN7409 activates CD40-mediated immune responses, stimulating antigen-presenting cells and promoting anti-tumor immunity. LVGN3616 blocks the inhibitory PD-1/PD-L1 pathway, restoring and enhancing T-cell mediated immune responses against tumors. This combination is under investigation primarily for metastatic solid tumors, aiming to boost the anti-cancer effect via dual immune activation pathways. Developed by Lyvgen Biopharma, it is being evaluated in combination regimens in phase 1 clinical trials, often with additional agents such as nab-paclitaxel, bevacizumab, and cyclophosphamide[1][2][4][5][6].
- Other names
- dalnicastobart + pradusinstobart
02
Targets
CD40 (Cluster of differentiation 40 receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on LVGN7409 + LVGN3616.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LVGN7409 + LVGN3616.